Researchers identified plasma phosphorylated tau biomarkers—pTau217 and pTau231—that forecast dementia progression in patients with Parkinson’s disease. The prospective longitudinal work aims to address the lack of reliable early indicators of cognitive decline in Parkinson’s. The study positions blood-based pTau assays as potential tools to stratify risk over time, moving dementia prognostication beyond clinical observation alone. If validated across broader cohorts, such biomarkers could influence trial enrichment and monitoring strategies in Parkinson’s disease. The reported findings come as PD management increasingly emphasizes early detection of neurodegenerative trajectories, including separate efforts to improve home and real-world monitoring approaches.